B of A Securities Maintains Neutral on Hims & Hers Health, Lowers Price Target to $21
B of A Securities analyst Allen Lutz maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and lowers the price target from $26 to $21.
Last updated: 2026-11-21 16:03:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Hims & Hers Health, Inc. (HIMS) operates in the SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE sector and is listed on NYSE. The stock is currently priced at $14.60, with a market capitalization of $3.76B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.74 to $40.99. This page covers its latest market performance, valuation, price trends and company information.
$3.76B | |
$15.51 | |
$15.95 | |
$14.51 | |
$16.02 | |
14.46M | |
11.92M | |
-- | |
$40.99 | |
$13.74 | |
-- | |
2026-09-30 |
Hims & Hers Health, Inc. (HIMS) last closed at $14.60 as of 2026-11-21 00:59:04, down 5.56% ($0.89) from the previous close of $16.02.
During the latest regular trading session, HIMS traded between $14.51 and $15.95, with a volume of 14.46M shares. The closing price was near the lower end and near the lower end of its 52-week range.
HIMS is up 0.53% as of the last close.
Over the past seven days, Hims & Hers Health, Inc. (HIMS) moved from $19.73 to $14.60, representing a decline of 26.01% ($5.13).
The stock traded between $14.51 and $20.46 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 12.62 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.1%
HIMS is currently trading at $14.60, placing it 3.1% of the way from its 52-week low of $13.74 to its 52-week high of $40.99. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2.7 million subscribers, is available in all 50 states and certain international markets including the UK, Germany, and Australia. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
| Industry | SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE |
| Employees | 2,442 |
| CEO | Andrew Dudum |
| Founded | 2017 |
| Exchange | NYSE |
| Company Website |
Latest news related to Hims & Hers Health, Inc. and HIMS stock.
B of A Securities analyst Allen Lutz maintains Hims & Hers Health (NYSE:HIMS) with a Neutral and lowers the price target from $26 to $21.
Hims & Hers Health stock plummeted following earnings results that revealed strong 49% revenue growth but concerning profitability issues. The company posted a $66.1 million operating loss compared to an $11.8 million profit a year ago, with gross margins deteriorating from 74% to 57%. The analyst recommends avoiding the stock until the company demonstrates sustainable profitable growth.
Hims & Hers stock crashed 17% after issuing weak Q4 guidance, with revenue projections falling short of analyst expectations at $875-895 million versus expected $955.1 million. The company faces margin pressure from increased sales of lower-margin weight-loss drugs and international expansion. However, the upcoming launch of its Peptides+ category at month-end could provide significant growth opportunities, making the stock potentially attractive for long-term investors despite current headwinds.
Hims & Hers (HIMS) reported Q3 2026 EPS of 3 cents, missing estimates by 57.1%, though revenues grew 48.7% year-over-year to $890.4 million. The company faced margin compression due to lower-margin weight loss products and a sequential subscriber decline of 100,000. HIMS lowered its full-year adjusted EBITDA guidance to $257-$277 million but raised international revenue outlook to at least $650 million.
Eligible investors can buy real shares of Hims & Hers Health, Inc. (HIMS) through MEXC Stocks. Follow these three steps to open a Stocks account, transfer USDT, and place a Stocks order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to HIMS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between HIMS shares and USD.
HIMS Shares to USD
1.00 HIMS shares = 14.598 USD
Calculations are estimates based on the latest available price and are for reference only.